Repligen (RGEN) Stock Surges – What's Behind the Rise?

This evening we watched Repligen rise 3.1% to a price of $127.0 per share. The Mid-Cap Biotechnology company is now trading -37.77% below its average target price of $204.08. Analysts have set target prices ranging from $165.0 to $225.0 per share for Repligen, and have given the stock an average rating of buy.

Repligen has an average level of shares sold short, at 9.1% of its total share float. The stock's short ratio (also called days to cover) is 8.27. Since 6.57% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Institutional investors own 102.4% of Repligen's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Repligen

Date Reported Holder Percentage Shares Value
2024-03-31 Blackrock Inc. 14% 7,773,131 $987,187,637
2024-03-31 Vanguard Group Inc 9% 5,100,013 $647,701,651
2024-03-31 Price (T.Rowe) Associates Inc 6% 3,568,316 $453,176,132
2024-03-31 FMR, LLC 4% 2,257,789 $286,739,203
2024-03-31 State Street Corporation 3% 1,758,212 $223,292,924
2024-03-31 Macquarie Group Limited 3% 1,464,602 $186,004,454
2024-03-31 Sands Capital Management, LLC 3% 1,432,737 $181,957,599
2024-03-31 Invesco Ltd. 2% 1,242,743 $157,828,361
2024-03-31 Brown Capital Management, LLC 2% 1,154,635 $146,638,645
2024-03-31 Bank Of New York Mellon Corporation 2% 1,132,491 $143,826,357
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.